Am­gen backs WuXi NextCODE’s $75M B round; Im­Check bags €20 ven­ture round for I-O work

→ The glob­al con­tract ge­nomics out­fit WuXi NextCODE raised a $75 mil­lion B round from an in­ter­na­tion­al con­sor­tium of in­vestors. Am­gen Ven­tures was in­volved, along with 3W Part­ners in a raise led by Temasek and Yun­feng Cap­i­tal. “Ge­nomics is the cross­road where da­ta and bi­ol­o­gy meet,” said Ge Li, chair­man of WuXi NextCODE and founder and chair­man of WuXi AppTec.

→ An­gling to hit the clin­ic in 2019 with new im­muno-on­col­o­gy drugs, France’s Im­Check has raised a €20 mil­lion Se­ries A round led by Boehringer In­gel­heim Ven­ture Fund, Kur­ma Part­ners, Id­in­vest and joined by Gimv and LSP. Based in Mar­seilles, the com­pa­ny is fo­cused on gam­ma-delta T cells. The biotech al­so ap­point­ed Pierre d’Epe­noux as chief ex­ec­u­tive of­fi­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER